Loading...
Loading...
PHIOW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 47.0K |
| Gross Profit | -47.0K |
| Operating Expense | 2,776.0K |
| Operating I/L | -2,780.0K |
| Other Income/Expense | -4.0K |
| Interest Income | 0.0K |
| Pretax | -2,780.0K |
| Income Tax Expense | -51.0K |
| Net Income/Loss | -2,780.0K |
Phio Pharmaceuticals Corp. is a biotechnology company specializing in immuno-oncology therapeutics. The company's INTASYL therapeutic platform targets the suppression of the immune system by tumors. Its product portfolio includes PH-762, which targets the checkpoint protein PD-1, PH-804 that targets the suppressive immune receptor TIGIT, and PH-790 which targets PD-L1 protein. These products are used in adoptive cell transfer (ACT) to enhance the immune response against cancer. Phio Pharmaceuticals has collaborations with leading organizations for the clinical development of novel T cell-based cancer immunotherapies, positioning itself as a key player in the immuno-oncology market.
